Business Context and Reporting Period
Company: Integra LifeSciences Holdings Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: December 12, 2024
Reporting Period: The filing reports on a corporate governance event occurring on December 12, 2024, regarding the adoption of a new executive compensation program effective January 1, 2025.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The primary material change reported is the adoption of a new Change in Control Severance Program. This program renews and updates the terms for specific executive participants whose previous arrangements were scheduled to expire on December 31, 2024.
Guidance, Outlook, and Management Commentary
Change in Control Severance Program Details
- Effective Date: January 1, 2025.
- Participants: Lea Knight (EVP/CFO), Robert T. Davis, Jr. (EVP/President - Tissue Technologies), Michael McBreen (EVP/President - Codman Specialty Surgical), Jeffrey Mosebrook (SVP/Finance), and Eric I. Schwartz (EVP/CLO/Secretary).
- Trigger Event: A "qualifying termination" (without cause or for good reason) occurring on or within two years following a "change in control" of the Company, provided the change in control occurs by December 31, 2025.
- Severance Benefits:
- Lump sum payment equal to 1.5 times the sum of annual base salary and target cash bonus (2 times for Ms. Knight).
- Pro rata portion of the target cash bonus for the partial fiscal year.
- Company-subsidized COBRA premium payments for up to 18 months.
- Company-paid outplacement services for up to 12 months.
- Payment of any unpaid short-term annual cash bonus for prior-year performance.
- Conditions: Receipt of benefits is subject to the delivery and non-revocation of a general release of claims.
- Excise Tax Provision: Includes a "best pay cap" reduction mechanism to mitigate Section 4999 excise taxes, ensuring the executive receives the greater of the net amount after reduction or the net amount without reduction.
- Term: Expires December 31, 2025, unless extended by the Compensation Committee. Automatically extends for two years following a change in control or until obligations are satisfied if a qualifying termination occurs.
Investor Verification Checklist
- Verify the specific definitions of "cause," "good reason," and "change in control" in the full text of Exhibit 10.1.
- Confirm the total potential liability exposure for the Company under the new severance terms for all five named executives.
- Review the Compensation Committee's rationale for the 2x multiplier specifically applied to the CFO compared to other executives.
- Assess the impact of the "best pay cap" provision on the net payout amounts in a hypothetical change in control scenario.